DFTX
Definium Therapeutics, Inc.
$20.87
+4.25%
$2.2B
No data for this timeframe.
Vol
Market Cap$2.2B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (95%)
Insider Activity0B / 3S
Insider Net $-$797.0K
Reddit Sentiment50° Neutral
SEC Reports1
Exchange Nasdaq·Sector Medicinal Chemicals & Botanical Products·Inc. A1·CIK 0001813814·Prev Close $20.02
Recent Activity
May 13, 2026
short_volume
Short Volume: DFTX — 56.5% short (0.3M / 0.5M)
Short: 294,561 | Exempt: 899 | TRF Vol: 521,136 | Short Ratio: 56.5% | Off-exchange volume (dark poo
Apr 27, 2026
SEC
Definium Therapeutics filed definitive additional proxy materials for its 2026 Annual General and Special Meeting to be
DEFA14A — Impact 2/10
Mar 25, 2026
Insider
Barrow Robert sold 24,431 shares
Chief Executive Officer @ $18.47 ($451.2K)
Mar 25, 2026
Insider
Karlin Daniel sold 8,018 shares
Chief Medical Officer @ $18.47 ($148.1K)
Mar 25, 2026
Insider
Sullivan Mark sold 10,702 shares
Chief Legal Officer @ $18.47 ($197.7K)
Price Targets
$39.47
+89.1% upside
Strong Buy
Current $20.87
Low $25.00
Median $38.00
High $70.00
15 analysts
$25.00
$70.00
Analyst Ratings
8Strong Buy
13Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 8, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Apr 22, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
| Apr 17, 2026 | Stifel | INITIATE | Buy |
| Apr 16, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Apr 10, 2026 | Piper Sandler | INITIATE | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.57 ▼ -15.4% | $-0.72 — $-0.44 | -13% YoY | 11 |
| Next Q | $-0.56 ▼ -12.9% | $-0.66 — $-0.43 | 28% YoY | 11 |
| Current FY | $-2.27 ▼ -17.5% | $-2.66 — $-1.85 | -10% YoY | 12 |
| Next FY | $-1.58 ▲ +7.5% | $-2.62 — $0.30 | 30% YoY | 11 |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 25, 2026 | Barrow Robert | SELL | $451.2K |
| Mar 25, 2026 | Karlin Daniel | SELL | $148.1K |
| Mar 25, 2026 | Sullivan Mark | SELL | $197.7K |
| Feb 3, 2026 | Wiley Matthew | A | $0.00 |
| Feb 3, 2026 | Roberts Brandi | A | $0.00 |
Reddit Sentiment
50°▲
Neutral
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
5 unique insiders with 3 transactions. Net insider value: -$797.0K ($0.00 bought, $797.0K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 25, 2026 | Barrow Robert | Chief Executive Officer | SELL | 24,431 | $18.47 | $451.2K |
| Mar 25, 2026 | Karlin Daniel | Chief Medical Officer | SELL | 8,018 | $18.47 | $148.1K |
| Mar 25, 2026 | Sullivan Mark | Chief Legal Officer | SELL | 10,702 | $18.47 | $197.7K |
| Feb 3, 2026 | Wiley Matthew T. | Chief Commercial Officer | A | 115,000 | $0.00 | $0.00 |
| Feb 3, 2026 | Roberts Brandi | Chief Financial Officer | A | 150,000 | $0.00 | $0.00 |
| Feb 3, 2026 | Sullivan Mark | Chief Legal Officer | A | 125,000 | $0.00 | $0.00 |
| Feb 3, 2026 | Karlin Daniel | Chief Medical Officer | A | 150,000 | $0.00 | $0.00 |
| Feb 3, 2026 | Barrow Robert | Chief Executive Officer | A | 320,000 | $0.00 | $0.00 |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 2.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (95% buy). Based on 22 analysts: 8 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$39.47 mean target
+89.1% upside
Strong Buy (1.25)
$25.00 Low
$70.00 High
| Metric | Value |
|---|---|
| Current Price | $20.87 |
| Target Low | $25.00 |
| Target Mean | $39.47 |
| Target Median | $38.00 |
| Target High | $70.00 |
| # Analysts | 15 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.57 | $-0.72 | $-0.44 | -13.1% | -15.4% | 0↑ 1↓ | $0.0B | 0.0% | 11 |
| Next Q 2026-09-30 |
$-0.56 | $-0.66 | $-0.43 | 28.4% | -12.9% | 0↑ 1↓ | $0.0B | 0.0% | 11 |
| Current FY 2026-12-31 |
$-2.27 | $-2.66 | $-1.85 | -10.4% | -17.5% | 1↑ 10↓ | $0.0B | 0.0% | 12 |
| Next FY 2027-12-31 |
$-1.58 | $-2.62 | $0.30 | 30.5% | +7.5% | 5↑ 5↓ | $0.0B | 0.0% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.565 | |
| 7d ago | $-0.525 | -0.040 |
| 30d ago | $-0.490 | -0.075 |
| 60d ago | $-0.490 | -0.075 |
| 90d ago | $-0.453 | -0.113 |
8 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 8, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Apr 22, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Apr 17, 2026 | Stifel | INITIATE | — | Buy |
| Apr 16, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Apr 10, 2026 | Piper Sandler | INITIATE | — | Overweight |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Jan 30, 2026 | Jefferies | INITIATE | — | Buy |
| Jan 23, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 8 | 13 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 7 | 12 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 7 | 13 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 6 | 13 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 5 | 13 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
6 mentions
2 bullish
2 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 20, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 20, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Apr 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 8, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 8, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
May 13, 2026
short_volume
Short Volume: DFTX — 56.5% short (0.3M / 0.5M)
Short: 294,561 | Exempt: 899 | TRF Vol: 521,136 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
DFTX Q1 2026 Earnings Scheduled — 2026-05-07
Apr 30, 2026
short_volume
Short Volume: DFTX — 56.2% short (0.4M / 0.7M)
Short: 412,127 | Exempt: 0 | TRF Vol: 733,328 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_volume
Short Volume: DFTX — 59.0% short (0.5M / 0.8M)
Short: 454,032 | Exempt: 0 | TRF Vol: 769,862 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: DFTX — 58.2% short (0.7M / 1.1M)
Short: 657,367 | Exempt: 60 | TRF Vol: 1,130,438 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_interest
FTD: DFTX — 32,345 shares ($0.7M) failed to deliver
Settlement: 20260406, Price: $20.68, FTD Value: $668,894.6, DEFINIUM THERAPEUTICS INC COM
Apr 2, 2026
short_interest
FTD: DFTX — 33,671 shares ($0.7M) failed to deliver
Settlement: 20260402, Price: $20.60, FTD Value: $693,622.6, DEFINIUM THERAPEUTICS INC COM
Mar 24, 2026
short_volume
Short Volume: DFTX — 63.8% short (0.4M / 0.6M)
Short: 375,031 | Exempt: 457 | TRF Vol: 587,396 | Short Ratio: 63.8% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
short_interest
FTD: DFTX — 160,815 shares ($3.0M) failed to deliver
Settlement: 20260323, Price: $18.40, FTD Value: $2,958,996, DEFINIUM THERAPEUTICS INC COM
Feb 26, 2026
earnings_calendar
DFTX Q4 2025 Earnings After Market Close — 2026-02-26